Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01458574 · ClinicalTrials.gov registry record · Phase 3
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 593
- Enrollment target
NCT01458574 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 593 participants.
The verdict
NCT01458574, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 593 participants
- Enrollment target
Study Summary
The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.
Interventions
- DRUG Placebo
- DRUG CP-690,550
- DRUG CP690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 593 participants |
| Start Date | 2012-07-20 |
| Est. Completion | 2016-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01458574
The ClinicalTrials.gov registry entry for NCT01458574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 593 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01458574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01458574 about?
NCT01458574 is a clinical study titled "A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis". The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and ...
What is the current status of trial NCT01458574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 593 participants. The study started on 2012-07-20. Estimated completion is 2016-05-27.
What interventions are being tested in trial NCT01458574?
The interventions under investigation include: Placebo (DRUG), CP-690,550 (DRUG), CP690,550 (DRUG).
Who is sponsoring clinical trial NCT01458574?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.